Gretchen Kimmick

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Hot flashes in breast cancer survivors and an association with calcium supplement use
    Gretchen Kimmick
    Medical Oncology, Wake Forest University School of Medicine, Winston Salem
    Int J Womens Health 2:291-4. 2010
  2. pmc Adjuvant hormonal therapy use among insured, low-income women with breast cancer
    Gretchen Kimmick
    Associate Professor of Medicine, Duke University Medical Center, Box 3204, Suite 3800 Duke South, Durham, NC 27710, USA
    J Clin Oncol 27:3445-51. 2009
  3. doi request reprint Adjuvant chemotherapy for breast cancer in older women: emerging evidence to aid in decision making
    Gretchen Kimmick
    Multidisciplinary Breast Program, Duke University Medical Center, Durham, NC 27710, USA
    Curr Treat Options Oncol 12:286-301. 2011
  4. ncbi request reprint Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001
    Gretchen G Kimmick
    Duke University Medical Center, Suite 3800 Duke S, Box 3204, Durham, NC 27710, USA
    J Clin Oncol 23:2201-7. 2005
  5. ncbi request reprint Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen
    Gretchen G Kimmick
    Wake Forest University School of Medicine, Comprehensive Cancer Center, Wake Forest University, Winston Salem, North Carolina, USA
    Breast J 12:114-22. 2006
  6. doi request reprint Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)
    G G Kimmick
    Duke University Medical Center, Duke South, Durham, NC 27710, USA
    Breast Cancer Res Treat 113:479-90. 2009
  7. pmc Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy
    Lee W Jones
    Duke Cancer Institute, Duke University Medical Center, Box 3085, Durham, NC 27710, USA
    Cancer Prev Res (Phila) 6:925-37. 2013
  8. ncbi request reprint Survival disadvantage among Medicaid-insured breast cancer patients treated with breast conserving surgery without radiation therapy
    Kristie Long Foley
    Division of Public Health Sciences, Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Breast Cancer Res Treat 101:207-14. 2007
  9. pmc Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women
    Kathryn E Weaver
    Department of Social Sciences and Health Policy, Medical Center Boulevard, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Am J Clin Oncol 36:181-7. 2013
  10. pmc Breast cancer patients' treatment expectations after exposure to the decision aid program adjuvant online: the influence of numeracy
    Isaac M Lipkus
    Duke University School of Nursing, Durham, NC, USA
    Med Decis Making 30:464-73. 2010

Detail Information

Publications18

  1. pmc Hot flashes in breast cancer survivors and an association with calcium supplement use
    Gretchen Kimmick
    Medical Oncology, Wake Forest University School of Medicine, Winston Salem
    Int J Womens Health 2:291-4. 2010
    ..In breast cancer survivors, we aimed to describe the frequency of hot flashes and night sweats, frequency and type of treatment, and the association of hot flashes and use of calcium supplements...
  2. pmc Adjuvant hormonal therapy use among insured, low-income women with breast cancer
    Gretchen Kimmick
    Associate Professor of Medicine, Duke University Medical Center, Box 3204, Suite 3800 Duke South, Durham, NC 27710, USA
    J Clin Oncol 27:3445-51. 2009
    ..Improving use of adjuvant hormonal therapy may lead to lower breast cancer-specific mortality in this population...
  3. doi request reprint Adjuvant chemotherapy for breast cancer in older women: emerging evidence to aid in decision making
    Gretchen Kimmick
    Multidisciplinary Breast Program, Duke University Medical Center, Durham, NC 27710, USA
    Curr Treat Options Oncol 12:286-301. 2011
    ..In addition, as always in oncology, physicians and patients should look for and participate in clinical trials that will define how to treat cancer, especially in older patients, in the future...
  4. ncbi request reprint Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001
    Gretchen G Kimmick
    Duke University Medical Center, Suite 3800 Duke S, Box 3204, Durham, NC 27710, USA
    J Clin Oncol 23:2201-7. 2005
    ..To design and test a geriatric educational intervention to improve accrual of cancer patients age 65 years and older to cooperative group-sponsored treatment trials...
  5. ncbi request reprint Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen
    Gretchen G Kimmick
    Wake Forest University School of Medicine, Comprehensive Cancer Center, Wake Forest University, Winston Salem, North Carolina, USA
    Breast J 12:114-22. 2006
    ..Sertraline decreases hot flashes in breast cancer survivors taking tamoxifen and women prefer sertraline to placebo. Further study of sertraline for the management of hot flashes is warranted...
  6. doi request reprint Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)
    G G Kimmick
    Duke University Medical Center, Duke South, Durham, NC 27710, USA
    Breast Cancer Res Treat 113:479-90. 2009
    ..To describe long-term results of a multimodality strategy for stage III breast cancer utilizing neoadjuvant doxorubicin followed by mastectomy, CMF, and radiotherapy...
  7. pmc Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy
    Lee W Jones
    Duke Cancer Institute, Duke University Medical Center, Box 3085, Durham, NC 27710, USA
    Cancer Prev Res (Phila) 6:925-37. 2013
    ..Data from this exploratory study provide initial evidence that AET can modulate several host- and tumor-related pathways during standard chemotherapy. The biologic and clinical implications remain to be determined...
  8. ncbi request reprint Survival disadvantage among Medicaid-insured breast cancer patients treated with breast conserving surgery without radiation therapy
    Kristie Long Foley
    Division of Public Health Sciences, Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Breast Cancer Res Treat 101:207-14. 2007
    ..It is possible that the prognostic significance of omission of RT in clinical trials underestimates the significance of risk in the community...
  9. pmc Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women
    Kathryn E Weaver
    Department of Social Sciences and Health Policy, Medical Center Boulevard, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Am J Clin Oncol 36:181-7. 2013
    ..We explored the relationship between adherence to tamoxifen or selective aromatase inhibitors with cancer recurrence and death in a low-income, Medicaid-insured population...
  10. pmc Breast cancer patients' treatment expectations after exposure to the decision aid program adjuvant online: the influence of numeracy
    Isaac M Lipkus
    Duke University School of Nursing, Durham, NC, USA
    Med Decis Making 30:464-73. 2010
    ..Results suggest that numeracy influences a patient's ability to interpret numerical estimates of treatment efficacy from decision aids such as Adjuvant!...
  11. ncbi request reprint Comorbidity burden and guideline-concordant care for breast cancer
    Gretchen Kimmick
    Department of Internal Medicine, Division of Oncology, Duke University Medical Center, Durham, North Carolina
    J Am Geriatr Soc 62:482-8. 2014
    ..To explore the relationship between level and type of comorbidity and guideline-concordant care for early-stage breast cancer...
  12. ncbi request reprint Breast cancer in older patients
    Gretchen Kimmick
    Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Semin Oncol 31:234-48. 2004
    ..The goals in treating metastatic breast cancer in an older patient are not different than for younger patients...
  13. ncbi request reprint Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041)
    Gretchen Kimmick
    Comprehensive Cancer Center of Wake Forest University, Winston Salem, NC 27157, USA
    Invest New Drugs 22:83-9. 2004
    ..Good performance status was the most important predictor of survival. In this group of women with metastatic breast cancer, the overall prognosis was poor. This combination of rIL-2 and IFN was ineffective...
  14. doi request reprint Multidisciplinary care of patients with early-stage breast cancer
    Gary H Lyman
    Comparative Effectiveness and Outcomes Research Program, Department of Medicine, Duke Cancer Institute, Duke University School of Medicine, Durham, NC 27705, USA
    Surg Oncol Clin N Am 22:299-317. 2013
    ..The essential role for coordinated involvement of the entire health care team in optimal management of patients with early-stage breast cancer is likely to increase further...
  15. ncbi request reprint Interpreting measures of treatment effect in cancer clinical trials
    L Douglas Case
    Department of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Oncologist 7:181-7. 2002
    ..The most common mistake is to interpret both measures as relative risks, an interpretation that can lead to an incorrect impression of the impact of the treatment on response and survival...
  16. pmc A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer
    Carey Anders
    Division of Medical Oncology, Duke University Department of Medicine, Durham, North Carolina, USA
    Cancer Invest 26:286-95. 2008
    ..5%. Conclusions: Results indicate that pre-chemotherapy Inhibin B and AMH are lower among women experiencing CRA and may be predictive of CRA among premenopausal women facing chemotherapy for ESBC...
  17. doi request reprint BMI influences prognosis following surgery and adjuvant chemotherapy for lymph node positive breast cancer
    Mara Z Vitolins
    Division of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Breast J 14:357-65. 2008
    ....
  18. ncbi request reprint Long-term follow-up of a phase II trial studying a weekly doxorubicin-based multiple drug adjuvant therapy for stage II node-positive carcinoma of the breast
    Gretchen G Kimmick
    The Comprehensive Cancer Center of Wake Forest University, Winston Salem, NC 27157 1082, USA
    Breast Cancer Res Treat 72:233-43. 2002
    ..This single-arm study aimed to evaluate the effectiveness of an intensive doxorubicin-based multidrug regimen as adjuvant therapy in women with stage II, node positive breast cancer...